DHMC part of trial for COVID-19 pneumonia treatment

Published: 5/20/2020 6:07:11 PM
Modified: 5/20/2020 6:07:03 PM

LEBANON — Researchers at Dartmouth-Hitchcock Medical Center are participating in a new “phase 3” study approved by the Food and Drug Administration to determine whether a drug known as lenzilumab can be used to treat patients hospitalized with pneumonia because of COVID-19.

DHMC will help assess whether lenzilumab, a monoclonal antibody developed by the California-based biopharmaceutical company Humanigen, prevents COVID-19-associated pneumonia from progressing to respiratory failure or death, Dartmouth-Hitchcock said in a news release on Wednesday.

A total of 238 patients at medical centers around the country, including DHMC, will receive either lenzilumab or a placebo to see if it works, alongside standard care practices to “alleviate the immune-mediated Cytokine Release Syndrome,” thereby reducing the need for invasive ventilators for COVID-19 pneumonia patients, the release said.

The study will be directed toward patients who have biomarkers indicating that they are at high risk for their COVID-19 pneumonia to get worse.

Valley News

24 Interchange Drive
West Lebanon, NH 03784


© 2020 Valley News
Terms & Conditions - Privacy Policy